ReachMD CME

CME credits: 1.00 Valid until: 30-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/classificationsuspecting-a-diagnosis-of-fnaitnait/32276/ Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can...

CME credits: 1.00 Valid until: 30-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/fetalneonatal-alloimmune-thrombocytopenia-fnait-the-platelet-equivalent-of-rh-disease/32275/ Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleedin...

CME credits: 1.00 Valid until: 30-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/the-alloimmune-disorders-of-pregnancy/32274/ Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed...

CME credits: 0.25 Claim your CME credit at https://reachmd.com/programs/cme/chairpersons-perspective-novel-treatments-for-newly-diagnosed-ph-cml-cp-striking-the-balance-of-treatment-with-patient-goals-and-qol/28646/ Although the first-generation tyrosine kinase inhibitors (TKIs) revolutionized the treatment of Ph+ CML-CP, the rate of resistance to these agents is high, and many patients require fu...

CME credits: 1.75 Valid until: 31-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/can-we-talk-optimizing-patient-buy-in-to-the-management-of-endometriosis/26296/ A paradigm change is occurring in the diagnosis and management of endometriosis. This change will help facilitate the earlier diagnosis of endometriosis and promote more widespread use of medical therapy as opposed to su...

CME credits: 1.75 Valid until: 31-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/pre-and-postoperative-use-of-gnrh-antagonists/26295/ A paradigm change is occurring in the diagnosis and management of endometriosis. This change will help facilitate the earlier diagnosis of endometriosis and promote more widespread use of medical therapy as opposed to surgery for many women. Accom...

CME credits: 1.75 Valid until: 31-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/the-integral-role-of-gnrh-antagonists-in-the-management-of-endometriosis/26294/ A paradigm change is occurring in the diagnosis and management of endometriosis. This change will help facilitate the earlier diagnosis of endometriosis and promote more widespread use of medical therapy as opposed to su...

CME credits: 1.75 Valid until: 31-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/changing-the-paradigm-in-the-management-of-endometriosis-moving-away-from-surgery-first-to-pharmacologic-therapy-first/26293/ A paradigm change is occurring in the diagnosis and management of endometriosis. This change will help facilitate the earlier diagnosis of endometriosis and promote more wide...

CME credits: 1.75 Valid until: 31-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/program-name/26292/ A paradigm change is occurring in the diagnosis and management of endometriosis. This change will help facilitate the earlier diagnosis of endometriosis and promote more widespread use of medical therapy as opposed to surgery for many women. Accompanying this change will be a mor...

CME credits: 1.75 Valid until: 31-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/early-diagnosis-its-pivotal-role-in-optimizing-outcomes-in-patients-with-endometriosis-psychosocial-and-physical-consequences/26288/ A paradigm change is occurring in the diagnosis and management of endometriosis. This change will help facilitate the earlier diagnosis of endometriosis and promote mo...

CME credits: 0.25 Claim your CME credit at https://reachmd.com/programs/cme/improving-outcomes-and-addressing-racial-disparities-in-patients-with-hrher2-early-breast-cancer-a-case-based-learning-lab/16199/ The emergence of the cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) has transformed the treatment landscape for patients with hormone receptor positive/human epidermal growth factor receptor 2...

CME credits: 0.25 Claim your CME credit at https://reachmd.com/programs/cme/expert-answers-to-common-questions-on-response-matters-transforming-the-standard-of-care-in-cml-by-mastering-response-guided-treatment/15663/ Chronic myeloid leukemia is a myeloproliferative neoplasm characterized by disordered growth of myeloid cells. The hallmark of chronic myeloid leukemia (CML) is an acquired reciproca...

CME credits: 0.50 Claim your CME credit at https://reachmd.com/programs/cme/chairpersons-perspective-cdk-46-inhibitors-practice-changing-implications-of-targeted-therapies-in-hrher2-breast-cancer/15715/ By 2040, the global breast cancer burden is expected to increase by 40%, resulting in more than 3 million new cases and 1 million deaths per year. Approximately 65% of cases among women less than 5...

Claim your CME credit at https://reachmd.com/programs/cme/should-we-look-for-gout-in-the-cardiology-clinic/15964/ This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate...

Claim your CME credit at https://reachmd.com/programs/cme/what-are-the-emerging-therapies-for-managing-gout/15963/ This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate...

Claim your CME credit at https://reachmd.com/programs/cme/whats-new-about-gout-rheumatology-perspective/15962/ This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate bur...

Claim your CME credit at https://reachmd.com/programs/cme/whats-new-about-gout-nephrology-perspective/15961/ This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burde...

Claim your CME credit at https://reachmd.com/programs/cme/can-you-manage-patients-with-uncontrolled-gout-more-effectively/15960/ This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to i...

Claim your CME credit at https://reachmd.com/programs/cme/treat-or-refer-who-is-responsible-for-managing-gout/15959/ This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased ura...

Claim your CME credit at https://reachmd.com/programs/cme/center-of-the-target-which-patients-are-most-likely-to-develop-gout/15958/ This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead...

Claim your CME credit at https://reachmd.com/programs/cme/is-managing-gout-in-the-nephrology-clinic-a-challenge/15957/ This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased u...

Claim your CME credit at https://reachmd.com/programs/cme/is-gout-hiding-in-the-nephrology-clinic/15956/ This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden an...

Claim your CME credit at https://reachmd.com/programs/cme/gout-beyond-the-joints-whats-the-hidden-danger/15955/ This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate bu...

CME credits: 0.25 Claim your CME credit at https://reachmd.com/programs/cme/expert-answers-to-common-questions-about-met-exon-14skipping-mutations-in-nsclc/14678/ Non-small cell lung cancer (NSCLC) is a highly heterogeneous disease, and research has evolved its diagnosis and treatment through the discovery of genetic alterations and molecular pathways, personalizing treatment based on tumor mutati...

CME credits: 1.00 Claim your CME credit at https://reachmd.com/programs/cme/improved-outcomes-in-mcrpc-with-psma-directed-diagnostics-and-therapies/13789/ Prostate-specific membrane antigen (PSMA) is highly expressed on prostate cancer (PC) cells and can be detected in tumors using positron emission tomography imaging. Even though clinical features predict different stages of PC progression, the a...